{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:21:33Z","timestamp":1762017693577,"version":"3.37.3"},"reference-count":51,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1124\/dmd.113.053074","type":"journal-article","created":{"date-parts":[[2013,8,31]],"date-time":"2013-08-31T04:20:34Z","timestamp":1377922834000},"page":"1957-1966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity"],"prefix":"10.1016","volume":"41","author":[{"given":"Vidya","family":"Perera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette S.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia B.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihem","family":"Ait-Oudhia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.113.053074_bib1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/biomet\/66.2.237","article-title":"A Bayesian extension of the minimum AIC procedure of autoregressive model fitting","volume":"66","author":"Akaike","year":"1979","journal-title":"Biometrika"},{"key":"10.1124\/dmd.113.053074_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1124\/mol.64.3.659","article-title":"Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1","volume":"64","author":"Aklillu","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-642-13443-2_3","article-title":"Pharmacokinetics and metabolism of natural methylxanthines in animal and man","volume":"200","author":"Arnaud","year":"2011","journal-title":"Handbook Exp Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/dmd.113.053074_bib5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0090-9556(25)07190-9","article-title":"Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes","volume":"19","author":"Berthou","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.053074_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0024-3205(95)00304-O","article-title":"Caffeine increases its own metabolism through cytochrome P4501A induction in rats","volume":"57","author":"Berthou","year":"1995","journal-title":"Life Sci"},{"key":"10.1124\/dmd.113.053074_bib51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00008571-199504000-00003","article-title":"Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans","volume":"5","author":"Berthou","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.113.053074_bib7","first-page":"725","article-title":"Comparison of theophylline and theobromine metabolism in man","volume":"13","author":"Birkett","year":"1985","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.053074_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2125.1991.tb05553.x","article-title":"Caffeine renal clearance and urine caffeine concentrations during steady state dosing. Implications for monitoring caffeine intake during sports events","volume":"31","author":"Birkett","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00613933","article-title":"The absolute bioavailability of caffeine in man","volume":"24","author":"Blanchard","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/clpt.1982.132","article-title":"Caffeine disposition after oral doses","volume":"32","author":"Bonati","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053074_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1365-2125.2010.03750.x","article-title":"Nonlinear pharmacokinetics of piperacillin in healthy volunteers\u2014implications for optimal dosage regimens","volume":"70","author":"Bulitta","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00008571-199206000-00003","article-title":"Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites","volume":"2","author":"Butler","year":"1992","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.113.053074_bib13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/clpt.1990.66","article-title":"Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function","volume":"47","author":"Cheng","year":"1990","journal-title":"Clin Pharmacol Ther"},{"year":"2009","series-title":"ADAPT 5 User\u2019s Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"D'Argenio","key":"10.1124\/dmd.113.053074_bib14"},{"key":"10.1124\/dmd.113.053074_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00315208","article-title":"Effects of caffeine with repeated dosing","volume":"40","author":"Denaro","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/clpt.1990.150","article-title":"Dose-dependency of caffeine metabolism with repeated dosing","volume":"48","author":"Denaro","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053074_bib17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00228-007-0438-6","article-title":"Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes","volume":"64","author":"Djordjevic","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1472-8206.2003.00136.x","article-title":"Two novel methods for the determination of CYP1A2 activity using the paraxanthine\/caffeine ratio","volume":"17","author":"Doude van Troostwijk","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x","article-title":"Assessment of CYP1A2 activity in clinical practice: why, how, and when?","volume":"97","author":"Faber","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.113.053074_bib20","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.37.5.1065","article-title":"Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.113.053074_bib21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-007-0288-2","article-title":"Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans","volume":"63","author":"Ghotbi","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-199204000-00004","article-title":"Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1","volume":"2","author":"Gu","year":"1992","journal-title":"Pharmacogenetics"},{"year":"2009","series-title":"Pharmacology: Principles and Practice","author":"Hacker","key":"10.1124\/dmd.113.053074_bib23"},{"key":"10.1124\/dmd.113.053074_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1152\/jappl.1990.68.1.44","article-title":"Effect of paraxanthine on FFA mobilization after intravenous caffeine administration in humans","volume":"68","author":"Hetzler","year":"1990","journal-title":"J Appl Physiol"},{"key":"10.1124\/dmd.113.053074_bib25","series-title":"Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring","first-page":"1","article-title":"Guidelines for collection and analysis of pharmacokinetic data","author":"Jusko","year":"1992"},{"key":"10.1124\/dmd.113.053074_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/BF01063122","article-title":"Nonlinear assessment of phenytoin bioavailability","volume":"4","author":"Jusko","year":"1976","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.113.053074_bib27","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/clpt.1993.63","article-title":"The use of caffeine for enzyme assays: a critical appraisal","volume":"53","author":"Kalow","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053074_bib28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/j.1552-4604.1997.tb04356.x","article-title":"Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans","volume":"37","author":"Kaplan","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib29","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0009-9236(97)90097-7","article-title":"Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity","volume":"61","author":"Lee","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053074_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-277X.2003.00477.x","article-title":"Caffeine ingestion and fluid balance: a review","volume":"16","author":"Maughan","year":"2003","journal-title":"J Hum Nutr Diet"},{"key":"10.1124\/dmd.113.053074_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/0265203021000007840","article-title":"Effects of caffeine on human health","volume":"20","author":"Nawrot","year":"2003","journal-title":"Food Addit Contam"},{"key":"10.1124\/dmd.113.053074_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00609587","article-title":"Plasma and salivary pharmacokinetics of caffeine in man","volume":"21","author":"Newton","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/anxi.3070010403","article-title":"Dose-response effects of intravenous caffeine in normal volunteers","volume":"1","author":"Nickell","year":"1994","journal-title":"Anxiety"},{"key":"10.1124\/dmd.113.053074_bib34","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/bmc.1419","article-title":"Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma","volume":"24","author":"Perera","year":"2010","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/dmd.113.053074_bib35","first-page":"511","article-title":"Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry","volume":"92","author":"Perera","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053074_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/1389200211209050667","article-title":"Measurement of CYP1A2 activity: a focus on caffeine as a probe","volume":"13","author":"Perera","year":"2012","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.113.053074_bib37","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.2042-7158.2012.01594.x","article-title":"Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans","volume":"65","author":"Perera","year":"2013","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib38","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1517\/17425255.2013.795540","article-title":"Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia","volume":"9","author":"Perera","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.113.053074_bib39","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.2042-7158.2011.01326.x","article-title":"Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics","volume":"63","author":"Perera","year":"2011","journal-title":"J Pharm Pharmacol"},{"year":"2013","series-title":"R: A Language and Environment for Statistical Computing","key":"10.1124\/dmd.113.053074_bib40"},{"key":"10.1124\/dmd.113.053074_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hep.1840040107","article-title":"Caffeine: a model compound for measuring liver function","volume":"4","author":"Renner","year":"1984","journal-title":"Hepatology"},{"key":"10.1124\/dmd.113.053074_bib42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00008571-199604000-00001","article-title":"Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment","volume":"6","author":"Rostami-Hodjegan","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.113.053074_bib43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1365-2125.1990.tb03686.x","article-title":"Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man","volume":"29","author":"Sesardic","year":"1990","journal-title":"Br J Clin Pharmacol"},{"year":"2000","series-title":"The Safety Aspects of Dietary Caffeine","author":"Smith","key":"10.1124\/dmd.113.053074_bib44"},{"key":"10.1124\/dmd.113.053074_bib45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-3565(25)33447-6","article-title":"Disposition of caffeine and its metabolites in man","volume":"224","author":"Tang-Liu","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.053074_bib46","first-page":"131","article-title":"Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test","volume":"9","author":"Tantcheva-Po\u00f3r","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.113.053074_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2125.1987.tb03003.x","article-title":"Accumulation of caffeine in healthy volunteers treated with furafylline","volume":"23","author":"Tarrus","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib48","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/0006-2952(94)90304-2","article-title":"Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms","volume":"47","author":"Tassaneeyakul","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.113.053074_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/bdd.2510060107","article-title":"Relationship between total body clearance of caffeine and urine flow rate in elderly men","volume":"6","author":"Trang","year":"1985","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.113.053074_bib50","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/004982598238895","article-title":"Determination of drug-metabolizing enzyme activity in vivo: pharmacokinetic and statistical issues","volume":"28","author":"Tucker","year":"1998","journal-title":"Xenobiotica"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.113.053074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:38:39Z","timestamp":1739907519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624115371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0090955624115371"],"URL":"https:\/\/doi.org\/10.1124\/dmd.113.053074","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.113.053074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}